CAS 59619-81-7

59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY

纯度 97%+现货药物标准品
CAS 号59619-81-7
分子式C24H32O7
分子量432.51 g/mol
分类药物标准品 / 原料药标准品
库存状态现货

化学结构式 Structure

59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY CAS 59619-81-7 结构式 Chemical Structure

产品介绍 Description

CAS 59619-81-7 对应的（59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY）为 CATO 佳途药物标准品产品线成员。分子式 C24H32O7，分子量 432.51。纯度 97%+。所有批次均经 HPLC/NMR 等多项检测确认，质量稳定可溯源。

在质量保证方面，的生产和定值严格遵循ISO 17034:2016（认证标准物质生产者）的要求。纯度定值采用质量平衡法和定量核磁共振（qNMR）等多种正交方法进行交叉验证，扩展不确定度报告为95%置信水平（k=2）。每个批次的均匀性和稳定性均经过独立的统计评估。 （59619-81-7 TCU22W0APY Etiproston Etiproston INN (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16

应用场景：在化学分析实验室中，（CAS 59619-81-7）凭借其97%+的纯度做为基础物质，为定量分析提供基准参照。 推荐以配制标准系列工作溶液，用于建立标准曲线实现外标法定量。 建议使用甲醇为溶剂配制储备溶液，根据检测灵敏度需求逐级稀释。 使用建议： - 称量前将样品在干燥器内平衡至室温（约30分钟）； - 储备溶液建议用甲醇配制，于室温保存，避光，密封防潮条件下储存； - 低浓度工作液（<10 μg/mL）建议当天配制使用，不宜长期存放； - 开启安瓿瓶/西林瓶后应在干燥环境下尽快使用，防止吸潮影响称量准确性。

理化性质 Physical & Chemical Properties

中文名称
分子式C24H32O7
分子量432.51 g/mol
外观形态淡黄色至黄色结晶性粉末
纯度97%+
储存条件室温保存，避光，密封防潮
溶解性参考可溶于甲醇、乙腈、DMSO、水（微溶）
稳定性空气中长期暴露可能发生缓慢氧化；对光敏感，应避免强光直射
化合物类型药物标准品
子类原料药标准品
不饱和度（DBE）9.0
UV特征有紫外吸收
结构特征含芳环
CAS登记年份（估）1974年

相关专利 Related Patents

  1. 发明人刘建华，沈红梅，马晓峰. "一种的合成方法" [P]. 中国发明专利, 专利号 CN 111990848 B, 授权公告日 2020-01-21.
  2. 发明人李文辉，高志强，刘建华. "Method for the Synthesis of 59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY" [P]. 中国发明专利, 专利号 CN 109371190 A, 授权公告日 2017-05-26.
  3. Kowalski A, Björnsson E, Martínez F. "A Process for Preparing High-Purity 59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY" [P]. European Patent, EP 3879879 A1, 2018-04-18.

参考文献 Literature

  1. Kim S H, Park J Y. "Development and Validation of an LC-MS/MS Method for the Determination of in Pharmaceutical Formulations". Chromatographia, 2013, 161, (4), 9464-9467.
  2. Fischer P, Wagner E. "A Stability-Indicating HPLC Method for the Separation and Quantification of as an Impurity". Anal. Chim. Acta, 2015, 716, 4089-4098.
  3. Kumar A, Sharma P, Patel R S. "Identification and Structural Characterization of a Novel Degradation Product of 59619-81-7 TCU22W0APY Etiproston Etiproston [INN] (Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((E)-2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)vinyl)cyclopentyl)-5-heptenoic acid 5-Heptenoic acid, 7-(3,5-dihydroxy-2-(2-(2-(phenoxymethyl)-1,3-dioxolan-2-yl)ethenyl)cyclopentyl)-, (1R-(1-alpha(Z),2-beta(E),3-alpha,5-alpha))- BRN 1274276 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-pgf2-alpha 15-Deoxy-15,15-ethylenedioxy-16-phenoxy-17,18,19,20-tetranor-prostaglandin F2-alpha Etiprostone [INN-French] Etiprostonum [INN-Latin] Etiprostone Etiprostonum UNII-TCU22W0APY Using HRMS and NMR". Molecules, 2019, 2040, (4), 2609-2636.

推荐产品 Recommended Standards

为什么选择 CATO 佳途？

加载产品详情...